Frequently Asked Questions

Stratica Biosciences is a biological intelligence company that transforms multimodal human biology into disease-specific foundation models supporting therapeutic response prediction, biomarker discovery, and precision medicine. We combine AI-powered computational modeling, translational science, and clinical partnerships to help organizations build and apply biological intelligence at scale.

Biological intelligence is the structured understanding of how disease behaves across cells, tissues, biofluids, patients, and time. Stratica builds biological intelligence by integrating multimodal human data with computational models, disease expertise, and translational validation workflows. The result is a more predictive view of disease progression, therapeutic response, and patient stratification.

A Disease Intelligence Program is a coordinated effort that connects biological samples, clinical data, disease expertise, multimodal profiling, computational modeling, and translational partnerships into a reusable disease-specific resource. These programs support therapeutic discovery, biomarker development, patient stratification, companion diagnostics, disease monitoring, and foundation model development.

Stratica is a strong fit if you are trying to understand disease biology, therapeutic response, biomarker discovery, patient stratification, target discovery, drug repurposing, or longitudinal disease monitoring. We work with partners ranging from focused research teams to enterprise-scale disease intelligence programs spanning multiple institutions and stakeholders.

Most engagements begin with a discovery conversation where we learn about your program, scientific question, available samples, existing data, and desired outcomes. From there, we help scope the right engagement model, which may include focused analysis, multimodal profiling, translational research support, disease foundation model development, or a larger disease intelligence program.

Stratica can work with a range of starting points, including FFPE tissue, frozen tissue, TMAs, pathology slides, spatial data, single-cell data, plasma, serum, saliva, ctDNA, proteomics datasets, clinical metadata, and longitudinal outcomes. You do not need every data type available at the start. We help determine which samples, assays, and analytical approaches are appropriate for your biological or therapeutic question.

Both. Stratica can analyze existing spatial, single-cell, imaging, proteomic, biofluids, and clinical datasets. We can also help design and coordinate new multimodal profiling programs, including tissue access, pathology review, assay selection, CRO coordination, data generation, computational analysis, and translational interpretation.

Stratica works with biopharma and biotechnology companies, AI-native therapeutics companies, disease foundations, academic medical centers, health systems, clinical trial networks, CROs, and technology partners. See the full list of partnership types on our Partnerships page.

Yes. Stratica helps disease foundations and advocacy organizations build disease intelligence programs by connecting patient communities, tissue access, clinical metadata, academic medical centers, biopharma partners, funders, multimodal profiling, and computational modeling into reusable disease resources. These programs can support therapeutic development, biomarker discovery, patient stratification, clinical trial readiness, and future partnership opportunities.

Yes. Stratica provides multimodal biological training data, disease models, responder biology, and translational validation frameworks for AI-driven drug discovery teams.

Stratica's primary disease modeling domain is human airway biology, including upper airway, lower airway, lung disease, COPD, asthma, ILD, IPF, LAM, transplantation, pulmonary fibrosis, inflammation, infection, and oncology. We also support programs across oncology, immune-mediated disease, autoimmune disease, rare disease, fibrotic disease, neurodegeneration, gastrointestinal disease, genitourinary disease, exocrine disease, cardiovascular disease, renal disease, hepatic disease, and other organ systems.

Computational tissue modeling means creating digital representations of human tissues that preserve cellular identity, spatial organization, molecular state, and clinical context. These models help reveal how cells interact, how disease progresses, how therapies affect tissue ecosystems, and which biomarkers may predict response.

Stratica integrates multimodal human biology to identify patterns associated with therapeutic response or resistance. As disease foundation models mature, they support responder biology analysis, patient stratification, and biomarker discovery.

Many AI biotech companies begin with models. Stratica begins with human biology. Our platform combines tissue access, biofluids, clinical outcomes, spatial biology, single-cell genomics, proteomics, disease expertise, translational validation, and proprietary AI systems into a unified biological intelligence infrastructure. This allows us to support not only analysis, but also disease intelligence program design, sample coordination, biomarker discovery, therapeutic response modeling, and clinical translation.

Human-in-the-loop quality control means that Stratica's scientific experts review and validate computational outputs before they are used for interpretation or decision-making. This is critical in translational biology, where cell states, tissue architecture, clinical context, and therapeutic response must be interpreted carefully and reproducibly.

Spatial biology captures not only which molecules are present in tissue, but where they are located and how cells are organized within their native environment. Stratica uses spatial biology alongside single-cell genomics, digital pathology, biofluids profiling, proteomics, clinical metadata, and computational modeling to build disease-specific biological intelligence systems.

StraticaOS is Stratica's biological intelligence operating system. It connects disease-specific foundation models, automated annotation engines, multimodal QC and segmentation models, containerized analytical workflows, virtual tissue modeling, and AI-assisted expert review into a unified platform for translational biology. StraticaOS supports cell annotation, spatial organization, multicellular interaction modeling, disease-state discovery, biomarker development, H&E inference, virtual staining, therapeutic response prediction, companion diagnostics, and in silico testing.

RosenBridge is the AI co-pilot and orchestration layer within StraticaOS. It helps expert scientific teams run analyses, inspect results, refine annotations, manage workflows, and translate multimodal biological data into interpretable disease intelligence. RosenBridge is not a standalone replacement for expert review; it is designed to support human-in-the-loop analysis for complex translational biology.

Data ownership, access, licensing, and usage rights are defined by contract and vary depending on the engagement model. Stratica supports flexible partnership structures across academic, foundation, healthcare, and commercial programs.

The best first step is to contact us with a brief description of your program, scientific question, available samples or data, and desired outcome. We can help determine whether a focused analysis, translational research program, disease intelligence initiative, platform deployment, or strategic partnership is the right fit.